News

Press Release
RepliCel’s Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems
8 years ago Mar 27, 2017
First-in-human clinical study meets primary endpoint demonstrating product safety and clinical potential for tendon regeneration...
Press Release
RepliCel’s Phase 1 Clinical Trial For Hair Loss Succeeds In Meeting Primary Endpoints
8 years ago Mar 13, 2017
Five-year safety data firmly establishes product safety and confirms ongoing clinical and product development strategyVANCOUVER,...
Press Release
RepliCel Pursues Non-Diluting Grant Funding to Accelerate Value Creation and Commercialization
8 years ago Mar 06, 2017
VANCOUVER, BC – March 7, 2017 – RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel”...
Press Release
RepliCel Life Sciences Announces Re-pricing of Warrants
8 years ago Mar 05, 2017
VANCOUVER, BC – March 6, 2017 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)...
Press Release
RepliCel Signs Two Key Service Partnerships for Final Prototype Manufacturing and Testing of its Dermal Injector
8 years ago Feb 27, 2017
VANCOUVER, BC – February 28, 2017 – RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel”...
Press Release
RepliCel Life Sciences Announces Closing of Brokered and Non-brokered Private Placement
8 years ago Feb 23, 2017
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...
Press Release
RepliCel Announces European Patents for its Innovative Dermal Injector Technologies
8 years ago Feb 08, 2017
RCI-02, RepliCel’s nearest-term commercial asset, enables game-changing reliability, reproducibility, and programmability of three-dimensional skin injections...
Press Release
Replicel Life Sciences Inc. Announces Brokered Private Placement
8 years ago Feb 06, 2017
VANCOUVER, BC – February 7, 2017 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)...
As Seen In
Podcast: Replicel Life Sciences CEO Lee Buckler on global expansion
8 years ago Feb 05, 2017
To listen to Podcast and View Transcript on Financial Post click here
Press Release
RepliCel Appoints Corporate Executive, Hugh Rogers to its Board of Directors
8 years ago Feb 02, 2017
VANCOUVER, BC – February 3, 2017 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP)...
As Seen In
Companies Flocking to Japan for Biotech Deals
8 years ago Jan 31, 2017
To read the full article as it appears on The Life Sciences Report, click here....
As Seen In
ESPN with Bill Daughtry
8 years ago Jan 27, 2017
Listen: http://www.espn.com/espnradio/newyork/play?id=18570324 (at the 1:38 mark)
As Seen In
RepliCel (RP.V) Should Benefit from Renewed Investor Focus, Sweeping Legislation on Cell Therapy
8 years ago Jan 23, 2017
View Article on Zacks Small Cap Research click here
As Seen In
Will 2017 be the year of Cell Therapies?
8 years ago Jan 19, 2017
To read the full article as it appears on The Huffington Post, click here. (1/20/17)While...
As Seen In
Emerging Biotech Companies at Cantech 2017
8 years ago Jan 17, 2017
ProMIS Neurosciences, RepliCel Life Sciences, and Critical Outcome Technologies take the stageView Article by Pia...
As Seen In
RepliCel – Using Cells for Healing
8 years ago Jan 15, 2017
View featured company Article on Advisor Access click here
As Seen In
RepliCel CEO Lee Buckler talks to Cantech Letter
8 years ago Jan 10, 2017
View Article by Nick Waddell on Cantech Letter click here (1/11/2017)...
Events
2017 EBD Biotech Showcase
8 years ago Jan 08, 2017
RepliCel presented and conducted one-on-one partnering meetings.
Press Release
RepliCel CEO Provides 2017 Forecast
8 years ago Jan 04, 2017
After a year of restructuring, RepliCel poised for multiple clinical trial data announcements and completion...
Press Release
The Jake Brown Show
8 years ago Dec 06, 2016
Episode 10: SNY’s Taylor Rooks, Stylist Megan Wilson, Replicel’s Lee Buckler Released Dec 07, 2016...

by Type

by Topic

by month

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.